A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI

Tzenge Lien Shih, Kuan Hung Lin, Ray Jade Chen, Ting Yu Chen, Wei Ting Kao, Jen Wei Liu, Hsueh Hsiao Wang, Hsien Yu Peng, Yu Yo Sun, Wan Jung Lu

研究成果: 雜誌貢獻文章同行評審

摘要

Naphthalimide derivatives have multiple biological activities, including antitumour and anti-inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5–10 μM) inhibited collagen- and convulxin- but not thrombin- or U46619-mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more potent and efficient antiplatelet agents while minimizing bleeding risk, which may offer a therapeutic potential for cardiovascular diseases.
原文英語
頁(從 - 到)9434-9446
頁數13
期刊Journal of Cellular and Molecular Medicine
25
發行號19
DOIs
出版狀態已發佈 - 10月 2021

ASJC Scopus subject areas

  • 分子醫學
  • 細胞生物學

指紋

深入研究「A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI」主題。共同形成了獨特的指紋。

引用此